Assembly Biosciences Inc. (ASMB)
10.06
0.12 (1.21%)
At close: Apr 22, 2025, 3:59 PM
1.21% (1D)
| Bid | 9.65 |
| Market Cap | 75.48M |
| Revenue (ttm) | 28.52M |
| Net Income (ttm) | -40.18M |
| EPS (ttm) | -6.69 |
| PE Ratio (ttm) | -1.5 |
| Forward PE | -1.65 |
| Analyst | Buy |
| Ask | 11.35 |
| Volume | 15,507 |
| Avg. Volume (20D) | 27,742 |
| Open | 9.98 |
| Previous Close | 9.94 |
| Day's Range | 9.82 - 10.40 |
| 52-Week Range | 7.75 - 19.93 |
| Beta | 0.66 |
About ASMB
Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also developing ABI-H3733 that has completed Phase 1a clinical study, and ABI-4334, which is in pre-clinical tri...
Industry Biotechnology
Sector Healthcare
IPO Date Dec 17, 2010
Employees 73
Stock Exchange NASDAQ
Ticker Symbol ASMB
Website https://www.assemblybio.com
Analyst Forecast
According to 3 analyst ratings, the average rating for ASMB stock is "Buy." The 12-month stock price forecast is $33, which is an increase of 228.06% from the latest price.
Stock ForecastsNext Earnings Release
Assembly Biosciences Inc. is scheduled to release its earnings on May 7, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
